Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2016 16:15 ET | Source: KemPharm

FDA Issues Complete Response Letter for Apadaz™ New Drug Application

CORALVILLE, Iowa, June 13, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary...
June 09, 2016 06:55 ET | Source: KemPharm

KemPharm Files NDA Amendment Request with FDA for Apadaz™

CORALVILLE, Iowa, June 09, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary...
June 06, 2016 08:05 ET | Source: Zevra Therapeutics

KemPharm to Present Data from Pharmacokinetic Trial for Investigational Prodrug Benzhydrocodone at the 2016 International Conference on Opioids

CORALVILLE, Iowa, June 06, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary...
May 18, 2016 17:17 ET | Source: Zevra Therapeutics

KemPharm, Inc. to Host Annual Meeting of Stockholders on Tuesday, May 24, 2016 at 9:00 a.m. ET

CORALVILLE, Iowa, May 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
May 12, 2016 16:05 ET | Source: Zevra Therapeutics

KemPharm, Inc. Reports First Quarter 2016 Results

Recent Clinical Development & Regulatory Highlights: Introduced Apadaz™ as the proprietary name for KP201/APAPFDA Advisory Committees voted 16 to 4 in support of Apadaz...
May 10, 2016 08:30 ET | Source: Zevra Therapeutics

KemPharm Receives “Fast Track” Designation for KP511, an Investigational Prodrug of Hydromorphone

CORALVILLE, Iowa, May 10, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,...
May 05, 2016 17:15 ET | Source: Zevra Therapeutics

Statement Regarding FDA Advisory Committee Meeting on KemPharm’s Abuse-Deterrent Product Candidate Apadaz™

CORALVILLE, Iowa, May 05, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
May 05, 2016 07:30 ET | Source: Zevra Therapeutics

FDA Advisory Committees To Review KemPharm’s Abuse-Deterrent Drug Candidate Apadaz™

Trading of KMPH Common Stock Halted KemPharm Conference Call Today at 6:15 p.m. ET CORALVILLE, Iowa, May 05, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty...
May 03, 2016 07:33 ET | Source: Zevra Therapeutics

KemPharm, Inc. to Report First Quarter 2016 Results

CORALVILLE, Iowa, May 03, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,...
April 19, 2016 08:05 ET | Source: Zevra Therapeutics

KemPharm Announces New Additions to Senior Leadership Team

Daniel L. Cohen, global public policy and government relations leader, appointed Executive Vice President, Government and Public Relations Rene A. Braeckman, Ph.D., clinical development expert,...